Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors

Liver Metastases of Small Intestine Neuroendocrine Tumors

(2015) Chanjuan Shi et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

(2015) B. Basu et al.   CLINICAL CANCER RESEARCH

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

(2015) Johanna C. Bendell et al.   INVESTIGATIONAL NEW DRUGS

Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1

(2015) T. Vandamme et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Correlation and discordance of tumour proliferation index and molecular imaging characteristics and their implications for treatment decisions and outcome pertaining to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumour

(2015) Sandip Basu et al.   NUCLEAR MEDICINE COMMUNICATIONS

Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition

(2015) Ilaria Passacantilli et al.   Oncotarget

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity

(2014) Andriy Marusyk et al.   NATURE

Genomic landscape of pancreatic neuroendocrine tumors

(2014) Niklas Gebauer   WORLD JOURNAL OF GASTROENTEROLOGY

Comparison of protocols for DNA extraction from long-term preserved formalin fixed tissues

(2013) Stefan Paireder et al.   ANALYTICAL BIOCHEMISTRY

Epidemiology of gastroenteropancreatic neuroendocrine tumours

(2013) M. Fraenkel et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

(2013) Kurt G. Pike et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience

(2013) J. C. Yao et al.   CANCER RESEARCH

mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin

(2013) S. A. Kang et al.   SCIENCE

ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors

(2012) Massimo Falconi et al.   NEUROENDOCRINOLOGY

Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT

(2011) Bernhard Svejda et al.   CANCER

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

(2011) Jaume Capdevila et al.   CANCER AND METASTASIS REVIEWS

Targeting PI3K/mTOR Signaling in Cancer

(2011) B. M. Emerling et al.   CANCER RESEARCH

The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors

(2011) Ben Lawrence et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

(2011) S. V. Bhagwat et al.   MOLECULAR CANCER THERAPEUTICS

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

(2011) Y. Jiao et al.   SCIENCE

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

(2010) Jonathan R. Strosberg et al.   CANCER

Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

(2010) Kathrin Zitzmann et al.   CANCER LETTERS

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

(2009) K. Yu et al.   CANCER RESEARCH

Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway

(2009) Edoardo Missiaglia et al.   JOURNAL OF CLINICAL ONCOLOGY

mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling

(2009) L.-A. Julien et al.   MOLECULAR AND CELLULAR BIOLOGY

A novel and universal method for microRNA RT-qPCR data normalization

(2009) Pieter Mestdagh et al.   GENOME BIOLOGY

QuantPrime - a flexible tool for reliable high-throughput primer design for quantitative PCR

(2008) Samuel Arvidsson et al.   BMC BIOINFORMATICS

Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors

(2008) T. R Halfdanarson et al.   ENDOCRINE-RELATED CANCER

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS